- Home
- HHS vs KTTA Comparison
HHS vs KTTA Comparison
Compare HHS & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | KTTA |
|---|---|---|
| Founded | 1923 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 26.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HHS | KTTA |
|---|---|---|
| Price | $3.06 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 10.1K | ★ 250.2K |
| Earning Date | 03-16-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $166,841,000.00 | N/A |
| Revenue This Year | $6.54 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.33 | $0.28 |
| 52 Week High | $5.54 | $3.85 |
Technical Indicators
Market Signals| Indicator | HHS | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 36.89 |
| Support Level | $2.92 | $0.86 |
| Resistance Level | $3.15 | $0.92 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 29.89 | 9.71 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).